Northwestern Mutual Wealth Management Co. grew its holdings in Humana Inc (NYSE:HUM) by 9.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,156 shares of the insurance provider’s stock after acquiring an additional 270 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Humana were worth $840,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new stake in shares of Humana in the fourth quarter valued at approximately $402,117,000. Millennium Management LLC boosted its holdings in shares of Humana by 254.8% in the 4th quarter. Millennium Management LLC now owns 503,066 shares of the insurance provider’s stock valued at $144,118,000 after purchasing an additional 361,263 shares in the last quarter. Ceredex Value Advisors LLC boosted its holdings in shares of Humana by 53.2% in the 4th quarter. Ceredex Value Advisors LLC now owns 726,423 shares of the insurance provider’s stock valued at $208,468,000 after purchasing an additional 252,341 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Humana by 130.5% in the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock valued at $124,712,000 after purchasing an additional 208,595 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in shares of Humana by 1.6% in the 1st quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after purchasing an additional 186,997 shares in the last quarter. Institutional investors own 92.61% of the company’s stock.
HUM has been the topic of a number of research analyst reports. SunTrust Banks reduced their target price on Humana to $300.00 in a report on Thursday, May 2nd. Morgan Stanley set a $331.00 target price on Humana and gave the company a “buy” rating in a report on Thursday, May 2nd. Citigroup reduced their target price on Humana from $362.00 to $302.00 and set a “buy” rating on the stock in a report on Thursday, May 2nd. UBS Group initiated coverage on Humana in a report on Tuesday, April 23rd. They issued a “neutral” rating and a $266.00 target price on the stock. Finally, Oppenheimer reduced their target price on Humana from $373.00 to $350.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $337.26.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.30 by $0.18. Humana had a return on equity of 20.77% and a net margin of 2.99%. The firm had revenue of $16.11 billion during the quarter, compared to analyst estimates of $15.67 billion. During the same period last year, the company posted $3.36 EPS. The business’s quarterly revenue was up 12.8% on a year-over-year basis. On average, equities analysts predict that Humana Inc will post 17.48 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s dividend payout ratio (DPR) is presently 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: Growth and Income Funds
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.